Exhibit 99.1
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
October 23, 2023
WATERTOWN, Mass. October 23, 2023
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that
Joanne Bryce, Chief Financial Officer, plans to depart the company. Disc has initiated a search to fill the position. To ensure an orderly transition, Ms. Bryce plans to remain with the company and oversee her current responsibilities until a
successor has been identified.
On behalf of the Board and the entire Disc team, I want to thank Joanne for her financial leadership and commitment
to the company. Joanne has been at Disc since its inception and under her tenure, established our corporate operations, oversaw our transition to a publicly traded company, and strengthened our balance sheet over multiple financings. said John
Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. It is through her contributions that we can enter the next chapter of growth and plan for late-stage development from a position of financial strength. Joanne will be missed
by all of us as a valued colleague and friend, and we wish her all the best.
It has been a privilege to be a part of the Disc story and to
see the company grow from a concept on a whiteboard to where it is today. Im immensely proud to have worked with this team and am inspired by their hard-work, talent and tireless dedication to patients. said Ms. Bryce. My time
with Disc has been both professionally and personally fulfilling, but with the company on firm footing and preparing to embark on the next phase of its journey, it is a good time for me to pursue other endeavors and ensure a smooth transition.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is
a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology,
specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Disc Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, express or implied statements regarding the expected departure timeline, search outcome and transition of Discs chief financial officer position and the Companys expectations regarding
its future growth, plans for late-stage development and its financial strength. The use of words such as, but not limited to, believe, expect, estimate, project, intend, future,
potential, continue, may, might, plan, will, should, seek, anticipate, or could or the negative of these terms and other similar
words or expressions that are intended to identify forward-looking statements.